Loading...
XSHE
300639
Market cap535mUSD
Dec 05, Last price  
5.93CNY
1D
1.19%
1Q
2.42%
IPO
37.57%
Name

Guangdong Hybribio Biotech Co Ltd

Chart & Performance

D1W1MN
XSHE:300639 chart
P/E
P/S
4.64
EPS
Div Yield, %
1.10%
Shrs. gr., 5y
1.62%
Rev. gr., 5y
2.26%
Revenues
816m
-26.16%
139,014,305182,717,806264,082,642344,833,859398,303,899479,085,119580,352,056729,392,8021,354,496,7592,673,022,9535,596,971,0561,104,453,848815,528,791
Net income
-655m
L
19,725,22329,169,94363,459,11465,212,17876,094,57893,210,017114,079,529147,290,874362,662,411852,160,1151,725,997,552140,472,219-654,881,994
CFO
79m
-75.93%
16,084,45822,890,92734,651,89648,469,07463,630,74879,165,08580,390,222112,831,785311,300,240631,341,7521,309,216,063327,233,67678,778,451
Dividend
May 23, 20240.065 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Guangdong Hybribio Biotech Co.,Ltd. engages in the research and development, manufacture, and sale of nucleic acid molecular diagnostic products for hospitals and medical institutes. It provides in-vitro diagnostic kits for human papilloma virus, sexually transmitted diseases (STD), thalassemia, and prenatal and postnatal. The company also offers STD real time PCR kits; hepatitis B virus real-time PCR kits and thalassemia genoarray diagnostic kits; hearing loss susceptibility genoarray diagnostic kits; COVID-19 real-time PCR kits; and devices/instruments, including automated nucleic acid extraction, automatic medical PCR analysis, flow-through hybridization, auto DNA extraction, and fluorescent quantitative detection systems, as well as after-sales technical service support. Its products are used in the fields of national screening, clinical, and research purposes. The company operates in the Asia Pacific, the South East Asia, the Middle East, Europe, Africa, and South America. Guangdong Hybribio Biotech Co.,Ltd. was founded in 2003 and is based in Sheung Wan, Hong Kong.
IPO date
Apr 12, 2017
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT